Abstract 2797
Background
Neoadjuvant chemotherapy is an accepted treatment method to improve the survival for advanced gastric cancer in worldwide. This phase II study, KSCC1601, aimed to investigate efficacy and safety of S-1 and Oxaliplatin for locally advanced gastric (LAGC) and esophago-gastric cancer (EGC).
Methods
Patients received oral S-1 40-60 mg twice daily on days 1 to 14 every 3 weeks plus intravenous oxaliplatin 130 mg/m2 on day 1 every 3 weeks for 3 courses, followed by gastrectomy with D2 lymphadenectomy. The primary endpoint was pathological response rate (pRR) according to the proportion of necrosis in the tumor: grade 0, no necrosis; grade 1a, < 1/3 necrosis; grade 1b, > 1/3 or < 2/3 necrosis; grade 2, > 2/3 or < all necrosis; and grade 3, all parts of the tumors affected by necrosis. A sample size of 46 was set according to one-sided significance level of 0.05 and power of 80% based on an exact binomial distribution, and assuming the null hypothesis of a 30% pRR and an alternative hypothesis of a 50% pRR. The incidence of anastomosis leakage in EGC was the main secondary endpoint. Other secondary endpoints were R0 resection rate, overall survival, relapse free survival and safety.
Results
Between 2016 April and 2017 July, 47 patients (24 EGC, 23 LAGC) were enrolled in this study. All patients were eligible for analysis. 42 patients (89.4%:95%CI 76.9-96.5) underwent surgery, and curative resection was performed in 41 patients. The rate of protocol treatment completeness was 42 patients (89.4%:95%CI 76.9-96.5%). pRR, the primary endpoint (grade 1b to 3), was 25 cases (59.5%:90%CI 45.7-72.3%) of primary lesions. The main toxicities of neoadjuvant chemotherapy were grade 3/4 thrombocytopenia (10.6%), neutropenia (6.4%), anemia (4.3%), grade 3/4 anorexia (12.8%). The number of anastomosis leakage so as to 20 EGC according to the Clavien–Dindo classification was 2 for grade IIIa, 2 for grade IIIb, and 1 for grade IV (25.0%:90%CI 10.4-45.6%). Survival data will be updated in further investigation.
Conclusions
The S-1 and oxaliplatin was well tolerated and is promising as a preoperative chemotherapy regimen for patients with LAGC and EGC.
Clinical trial identification
UMIN000021061.
Legal entity responsible for the study
KSCC.
Funding
Yakult Honsha Co., Ltd., Cres Kyushu.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4162 - ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer
Presenter: Anu Moilanen
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3747 - HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch.
Presenter: Roman Dubianski
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4688 - Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four Consensus Molecular Subtypes.
Presenter: Pietro Paolo Vitiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
498 - Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.
Presenter: Xiao Fu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3731 - Effect of the polymorphism rs2470893 of the CYP1A1 gene on ovarian and endometrial cancer in Mediterranean women
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1215 - Cisplatin in NIPEC or HIPEC?
Presenter: Ivan Alvovsky
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2738 - Matrix metalloproteinase-mediated regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment
Presenter: MARIKO HIRAI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2190 - Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis
Presenter: Priya Sriskandarajah
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4482 - Functional inhibition of TGF-_ in colorectal cancer cells and its interaction with AXL receptor
Presenter: Davide Ciardiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
624 - Isoform-specific AKT Inhibition Differentially Affects Cell Functions in Pancreatic Adenocarcinoma
Presenter: Hugo Arasanz
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract